Bristol-Myers Squibb's $30B Dealmaking Spree Meets Its Data-Rich Reckoning in 2026

BMS posted $48.2B in FY2025 revenue, held flat YoY, as its Growth Portfolio surged 17% to offset accelerating legacy drug declines. With six pivotal pipeline readouts expected in 2026 and Eliquis patent cliffs approaching, CEO Chris Boerner's bet on a predict-first AI R&D strategy and aggressive M&A is entering its proof-of-concept year.

BMY · Health Care · March 14, 2026

S&P 500 Position

BMS sits in the middle tier of large-cap pharma within the S&P 500 Health Care sector. It trails Eli Lilly (~$750B), Johnson & Johnson (~$370B), AbbVie (~$330B), and Merck (~$250B) by market cap. At $120B, it's roughly peer to Amgen and ahead of Gilead and Regeneron. The competitive dynamic is defined by patent cliff severity: Leerink estimates 64% of BMS's 2025 revenue is exposed to LOE through 2030, the highest among large-cap peers. Merck faces a similar cliff with Keytruda (2028), creating an industry-wide scramble for next-generation pipeline assets.

Index Weight: ~0.25% | Rank: ~70-80 in S&P 500 by market cap

Company Overview

Bristol-Myers Squibb is executing one of the most complex portfolio transitions in pharmaceutical history. The company is simultaneously managing the decline of legacy blockbusters — Revlimid, Pomalyst, Sprycel, and eventually Eliquis — while scaling a Growth Portfolio that crossed a critical threshold in Q4 2025: nearly 60% of total revenue. Opdivo hit $10B in annual sales for 2025, Breyanzi delivered blockbuster-level CAR-T revenues, Camzyos is redefining hypertrophic cardiomyopathy treatment, and Cobenfy (the Karuna Therapeutics acquisition) is the first new mechanism-of-action schizophrenia drug in decades, though its $155M launch year fell below the Street's most optimistic targets. The competitive positioning is stark. BMS faces the steepest patent cliff among large-cap pharma: roughly 64% of its estimated revenue is subject to loss-of-exclusivity through the end of the decade. Eliquis European patents expire late 2026, U.S. generics hit April 2028, and Opdivo IV loses U.S. exclusivity around end-2028 — with Amgen's biosimilar ABP 206 Phase 3 trial now completed. BMS's response: $30B in deals over two years under Boerner, the launch of subcutaneous Opdivo Qvantig to defend franchise share, and a pipeline targeting 10+ new medicines and 30+ label expansions by 2030. The six pivotal readouts expected in 2026 — milvexian (cardiovascular), admilparant (pulmonary fibrosis), iberdomide, mezigdomide, arlo-cel (hematology), and RYZ101 (radioligand therapy) — will determine whether BMS can achieve the sustainable growth trajectory Boerner has promised. The technical story that makes BMS interesting right now is its commitment to becoming what leadership calls 'the first truly predictive biopharmaceutical company.' The $74B Celgene acquisition in 2019 delivered not just pipeline assets but a massive longitudinal clinical data repository that now powers AI/ML-driven drug discovery across BMS's entire R&D continuum. This is a company where data infrastructure strategy and therapeutic strategy are converging.

Products & Revenue

BMS organizes its portfolio into Growth and Legacy buckets. The Growth Portfolio — Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Breyanzi, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, Cobenfy, and Opdivo Qvantig — generated $26.4B in FY2025, up 17% YoY, and now represents more than half of total revenue. The Legacy Portfolio — Eliquis, Revlimid, Pomalyst, Sprycel, Abraxane — produced $21.7B, down 16%, dragged by generic erosion on everything except Eliquis (which grew 7%). Alliance and other revenues contributed ~$1.4B. The critical dynamic: Growth Portfolio momentum must accelerate to absorb Eliquis's coming cliff, which management projects as a $1.5B-$2B revenue step-down in 2027 alone.

Eliquis (Anticoagulant) (~28%): Oral Factor Xa inhibitor co-developed with Pfizer for stroke prevention in atrial fibrillation and DVT/PE treatment. Top-selling drug, still growing at 7% in 2025, but faces IRA pricing pressure in 2026 and EU generic entry late 2026, U.S. generics April 2028.

Opdivo / Opdivo Qvantig / Opdualag (Immuno-Oncology) (~25%): PD-1 checkpoint inhibitor franchise with 15+ approved indications. Opdivo hit $10B in 2025 annual sales. Qvantig (subcutaneous formulation, FDA approved Dec 2024) takes <5 min vs 30 min IV infusion — a key lifecycle management play against coming biosimilars. Opdualag (nivolumab + relatlimab) holds >30% market share in metastatic melanoma.

Hematology (Revlimid, Pomalyst, Reblozyl, Abecma, Breyanzi) (~22%): Legacy myeloma franchises (Revlimid, Pomalyst) in steep generic decline, offset by rapid growth of next-gen assets: Reblozyl (luspatercept for anemia), Breyanzi (CAR-T, now approved for 5 cancer types), and Abecma (BCMA-targeted CAR-T). CELMoD agents iberdomide and mezigdomide are the pipeline successors.

Orencia / Zeposia / Sotyktu (Immunology) (~10%): Orencia (abatacept) for rheumatoid arthritis generated ~$3.7B in FY2024. Zeposia (S1P modulator) for ulcerative colitis and MS. Sotyktu (TYK2 inhibitor) for plaque psoriasis with recent psoriatic arthritis FDA approval (March 2026).

Cardiovascular (Camzyos, Eliquis Alliance) (~5%): Camzyos (mavacamten), the first cardiac myosin inhibitor for obstructive HCM, delivered blockbuster-level sales in 2025 with simplified monitoring. Milvexian (oral Factor XIa inhibitor, co-developed with J&J) in Phase 3 for atrial fibrillation and stroke prevention.

Neuroscience (Cobenfy) (~1%): Cobenfy (xanomeline/trospium), acquired via Karuna Therapeutics, is the first muscarinic agonist for schizophrenia in decades. $155M in launch-year sales with 100K+ prescriptions. Pipeline expansion into Alzheimer's psychosis (ADEPT trials) could be the growth inflection.

Based on FY2025 full-year earnings press release (February 5, 2026) and Q4 2025 10-K data. Revenue percentages are approximate calculations from reported segment figures.

Leadership

Christopher Boerner, Ph.D.

CEO since 2023. Boerner became CEO in November 2023 and added Board Chair in 2024. He previously served as Chief Commercialization Officer and led BMS's international markets. Before BMS, he held commercial leadership roles at Seattle Genetics (now Seagen), Genentech/Roche, and McKinsey. His PhD background and commercial-first orientation distinguish him from the typical physician-CEO model at large pharma — he's the dealmaker archetype, having closed $30B in transactions in his first two years as CEO.

Robert Plenge, M.D., Ph.D., EVP, Chief Research Officer & Head of Research: Plenge leads BMS's entire discovery engine, including the 'predict-first' AI/ML strategy. He came up through Celgene's immunology unit and has been instrumental in building the data-centric R&D framework that integrates causal human biology with generative molecular design.

Cristian Massacesi, M.D., EVP, Chief Medical Officer & Head of Development: Joined BMS in August 2025 from AstraZeneca, replacing Samit Hirawat. Oversees early- and late-stage clinical development across all therapeutic areas. He championed the February 2026 Evinova AI collaboration for clinical trial optimization. His appointment signals an urgency to improve clinical execution after several Phase 3 setbacks in 2025.

David Elkins, EVP & Chief Financial Officer: Elkins orchestrated the $10B accelerated debt paydown and the $2B cost-savings productivity initiative. He's guiding BMS through the complex financial engineering required to maintain the dividend (4.3% yield, 17 consecutive raises) while investing in pipeline and M&A.

Adam Lenkowsky, Chief Commercialization Officer: Leads the global launch execution for Cobenfy, Opdivo Qvantig, and the Growth Portfolio ramp. His team is responsible for converting clinical approvals into market share, including building the AI-enabled commercialization model for physician engagement.

The AI Angle

Predict first: AI as the drug discovery operating system

BMS has declared its ambition to become 'the first truly predictive biopharmaceutical company,' and the strategy is more than rhetoric. The company's 'predict-first' framework applies AI/ML across four integrated layers: causal human biology for target identification, predictive molecule design using generative models, patient segmentation and dosing optimization through clinical trial AI, and reinforcement learning-driven physician engagement in commercialization. Every small molecule in BMS's current portfolio now runs through predict-first screening — candidates advance only when computational models forecast high probability of success. The CELMoD sickle cell disease program is a direct product of this approach, where AI broke through a plateau in identifying a viable clinical candidate for targeted protein degradation. The infrastructure strategy is partnership-heavy rather than pure in-house build. BMS extended its AI drug discovery collaboration with insitro through 2025 (total deal value potentially exceeding $2B), using insitro's ChemML platform and iPSC models for ALS research. In December 2024, BMS signed a $400M collaboration with AI Proteins for miniprotein therapeutic discovery. In February 2026, BMS deployed Evinova's AI-native Study Designer platform (built by AstraZeneca's health tech subsidiary) across its entire global clinical trial portfolio for cost optimization — a tool that has demonstrated 5-7% savings per study. BMS also partnered with Accenture to implement over 30 generative AI solutions across R&D, manufacturing, and commercialization, including the 'Workbench' platform adopted by 30+ priority clinical trial teams with nearly 900 active users. Internally, BMS has deployed a custom in-house ChatGPT instance and the MyGrowth AI-powered HR platform. The Celgene acquisition delivered a data moat that underpins the entire AI strategy. Two decades of longitudinal clinical and real-world data in hematologic oncology and immunology provide the high-quality training sets that are the scarcest resource in pharmaceutical AI. BMS's Global Biometrics and Data Sciences team (based in Princeton) publishes actively on AI/ML methods for clinical trial optimization and external control arm design. Stephen Johnson, Ph.D. (Scientific VP, Discovery and Development Sciences) leads the predictive molecule invention work, while Kai Wang, Ph.D. (Executive Director, Informatics and Predictive Sciences) drives AI-driven protein degradation research. The competitive risk is real. Pfizer claims it can compress drug discovery to 30 days with its ML Research unit. Roche and Novartis are making parallel bets. Amgen's completed Phase 3 for an Opdivo biosimilar shows that even AI-optimized lifecycle management can't fully insulate against patent cliffs. BMS's bet is that integrated, data-centric AI — where discovery, development, and commercialization form a self-reinforcing loop — creates a systemic advantage that siloed AI deployments at competitors cannot match. The 2026 pivotal readouts for milvexian and admilparant will be partial proof points for whether predict-first translates into higher Phase 3 success rates.

Financial Snapshot

Revenue (TTM): $48.2B — TTM (FY2025 ending Dec 31, 2025) | Net Income: $7.1B GAAP net income ($12.5B non-GAAP)

Margins: Gross 71.1% GAAP (72.6% non-GAAP), SG&A 15.1% of revenue, Net 14.6% GAAP

BMS ended 2025 with ~$11B in cash, equivalents, and marketable securities and generated ~$14.7B in free cash flow. The company completed a targeted $10B debt paydown ahead of schedule while maintaining a 4.3% dividend yield with 17 consecutive annual increases. 2026 guidance projects $46B-$47.5B revenue (a 1-5% decline reflecting legacy erosion) with non-GAAP EPS of $6.05-$6.35 and operating expense reduction to ~$16.3B — evidence that the $2B productivity initiative is delivering. The key financial question: can Growth Portfolio acceleration and new launches replace the projected $15-20B+ in cumulative revenue losses from Eliquis and Opdivo LOE over the next 5-7 years?

1-Year Performance

BMY trades at $59.08 as of March 14, 2026. The stock hit a 52-week low of $42.52 on October 29, 2025 before rallying ~39% to reach a 52-week high of $63.33 on February 6, 2026, shortly after Q4 results beat consensus.

The Q4 2025 earnings beat ($12.5B revenue vs $12.24B consensus, $1.26 non-GAAP EPS vs $1.12 expected) catalyzed a sharp re-rating. UBS raised its price target to $70, and Barclays named BMY a top pharma pick alongside Eli Lilly. The stock benefits from a defensive profile (0.27 beta) and strong income appeal in a volatile market where biotech has been the one consistent sector winner in 2026. The key risk overhang remains the Eliquis cliff — any deterioration in pipeline readout expectations (particularly milvexian or iberdomide) could reverse the recent momentum.

Recent News

Fun Fact: When BMS received the National Medal of Technology from President Clinton in 1999, the citation specifically praised the company for 'redefining the science of clinical study through groundbreaking and hugely complex clinical trials.' The irony is that BMS is now using AI to dismantle the very clinical trial paradigm it helped create — its predict-first strategy aims to replace the iterative, brute-force trial-and-error model with computational prediction, essentially automating away the manual excellence it was awarded for. BMS also holds over 29,200 global patents (12,363 granted), and its protein degrader portfolio makes it the only company to have both discovered and commercialized this drug class — a distinction rooted in the serendipitous observation that thalidomide analogs (like Revlimid) were destroying disease-causing proteins through a mechanism nobody initially understood.